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ABSTRACT 
 
EFFECT OF NATURAL ANTIOXIDANTS ON MOTOR AND COGNITIVE DEFICITS IN 
AN ANIMAL MODEL OF AGING AND OBESITY AND DOPAMINERGIC-LIKE SH-SY5Y 
CELL LINE 
 
 
By  
Sneha Deepak Potdar 
August 2018 
 
Dissertation supervised by Jane E. Cavanaugh, Ph.D. 
Aging is a universal phenomenon. One of the greatest challenges faced by the elderly population 
is to sustain a healthy standard of living. Advancing age is associated with increased motor and 
cognitive deficits. Loss of balance, falls, hip fractures, and poor memory all contribute to a 
decline in the quality of life of the aging population. While ongoing research is making advances 
to find therapeutic interventions for neurodegenerative disorders like Parkinson’s and 
Alzheimer’s diseases, there is a pressing need to address deficits associated with normal aging. 
Increase in oxidative stress and a decline of antioxidant mechanisms with aging have 
been attributed to the incidence of deteriorated physical function, which is purported to 
commence in middle age. Therefore, in this study, we explored natural antioxidants that may 
have the potential to combat rising oxidative stress and weakening of physiological systems, 
thereby improving motor and cognitive function of the older population. We supplemented the 
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diet of middle-aged mice with resveratrol, a phytoalexin found in grapes, peanuts, wild blueberry 
and red wine. Resveratrol is known for its antioxidant, anti-inflammatory, anti-cancer properties 
and is also shown to be neuroprotective. During the course of our study, an unexpected 
confounding factor in the form of weight gain was introduced. However, by controlling for the 
increased bodyweight, we were able to evaluate resveratrol-mediated behavioral and molecular 
changes in a novel over-eating induced obesity and aging model. Our results indicated that 
prolonged resveratrol supplementation affected molecular changes in the brain, muscle and bone 
that may be potentially be beneficial for combating obesity and aging related deficits. 
In addition to resveratrol, we also tested its naturally occurring analog, piceid in an in vitro 
model of oxidative-stress induced cell death in a dopaminergic-like cell line. Piceid afforded 
neuroprotection against oxidative-stress induced toxicity via activation of ERK1/2 and ERK5 
(extracellular signal-regulated kinases) as well as inhibition of cellular apoptosis.  
In conclusion, our data suggest that natural antioxidants may combat physiological deficits 
induced by obesity and aging and maybe potential therapeutic interventions for improving the 
quality of life of the elderly. 
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CHAPTER ONE 
 
INTRODUCTION AND RATIONALE 
 
The number of people aged 65 and more in the Unites States is projected to reach about 80 
million by 2050 1. One of the challenges faced by the elderly is to maintain a healthy lifestyle 
and a good quality of life. Increasing age leaves the population susceptible to neurodegenerative 
disorders such as Parkinson’s 2-4 and Alzheimer’s 5-7. Additionally, with normal aging there is a 
decline of motor co-ordination accompanied by a concurrent rise in incidences of falls, loss of 
balance, fractures and augmented pain 8-12. Aging is also associated with impaired memory and 
cognition 13-15. As a result, substantial healthcare costs are associated with the elderly. Health 
care cost per capita for people older than 65 is about 3-5 times in the Unites States and other 
developed nations compared to persons <65 years 16. Depressive symptoms are associated with 
decrease in physical health and quality of life 17-19. 
Most therapeutic interventions are developed for neurodegenerative disorders. However, it is 
important to address declining physical health with increasing age in order to afford a better 
quality of life to the elderly population. Our study was aimed towards identifying potential 
therapeutic/prophylactic targets for age-related motor and cognitive deficits.   
Aging and oxidative stress 
The free radical theory of aging postulates that damage to cellular components and 
macromolecules is induced by highly reactive free radicals or reactive oxygen species, atoms or 
groups of atoms with an unpaired electron [hydroxyl radical (ꞏOH), superoxide anion (O2 −), 
hydrogen peroxide (H2O2)]. Aging renders the antioxidant defenses in the body less effective in 
counteracting the reactive oxygen species, thereby damaging critical cellular components 
including proteins, DNA and lipids 20-22. Aerobic respiration involving molecular oxygen and 
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catalyzed by oxidative enzymes and trace metals are the most likely source of reactive oxygen 
species 22. This theory was supported by the discovery of superoxide dismutase in 1969, an 
enzyme solely dedicated to removal of superoxide anions 23. As majority of the reactions 
involving molecular oxygen occur in the mitochondria, the electron transport chain (ETC) in the 
mitochondria is the source of majority of the reactive oxygen species 20, 24-25. Electrons that leak 
from the ETC can react with oxygen to produce free radicals 26-27. The cell has antioxidant 
defenses such as enzymes including thioredoxin peroxidase, catalase and glutathione peroxidase 
28-29 to combat free radicals and prevent cellular damage. However, these defenses decline with 
increasing age 30. Mitochondrial function and amount of mitochondrial DNA are also known to 
tissue-specifically decline with increasing age 31-33 leaving tissues vulnerable to mitochondrial 
dysfunction. 
Aging, oxidative stress, motor function and cognition 
Age-related oxidative stress is implicated in loss of motor co-ordination and cognitive abilities. 
A study by 34 examined the relationship between oxidative damage in the brain, motor skills and 
cognitive function in old (22 month) mice. They found that with increasing oxidative stress in the 
brain, motor and cognitive abilities declined. There was no co-relation between the degrees of 
cognitive and motor impairments indicating that the dysfunctions resulted from damage to 
separate regions of the brain.  In a study by 35, motor and cognitive loss was seen to manifest in 
middle and old age. This is an important finding as including only young and old age groups 
makes it difficult to discern fine changes that may have an onset in the middle age (40-50 years 
in humans). Previously, 36 observed motor function deficits beginning to occur in 12-month-old 
middle-aged mice.  Therefore, our rationale in this study was to start therapeutic intervention in 
middle age to possibly attenuate or prevent the onset of motor and cognitive deficits.   
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Natural antioxidants in aging, motor function and cognition 
Naturally occurring polyphenols are widely used as food and medicines 37-38. Over 10,000 
polyphenols possessing different bioactivities have been identified in fruits, vegetables, teas and 
medicinal plants 39-42. They are touted for their health benefits in age-related disorders, cancer, 
cardiovascular diseases and especially antioxidant potential 43-44. Studies have found a diet rich 
in polyphenols to improve cognitive and sensorimotor functions in aging mice 45. 
Studies by our lab and others 35-36 have established the importance of a middle-aged group in 
aging studies. Resveratrol (3, 4’, 5-trihydroxystilbene), a natural phytoalexin, is found in 
peanuts, grapes, wild blueberries and red wine. It is synthesized de novo as an antimicrobial and 
antioxidant defense in plants in response to stress, injury, U.V. radiation or attack by pathogens 
46-47. Resveratrol has shown promise in many in vitro and in vivo studies. In cancer models, 
resveratrol prevented DNA binding of (NF)-Κβ, a transcription factor that is up regulated and 
drives tumor proliferation of cancer cells, reduced tumor cell proliferation by inhibiting 
cyclooxygenase and promoted tumor cell apoptosis by promoting cell cycle arrest 48-50. Studies 
have also shown resveratrol’s beneficial effects against inflammation 51 and its role in extending 
lifespan of multiple organisms 52.  
Resveratrol in clinical studies 
 
Resveratrol has been tested for its therapeutic potential in several clinical trials, primarily for 
cancer, neurological disorders, diabetes and obesity and cardiovascular diseases 53. Consumption 
of 0.5 to 1.0g of resveratrol per day for 8 days was found to reduce colorectal tumor proliferation 
in twenty patients 54. A 12-week administration of 0.5-5mg twice-daily reduced methylation of 
the tumor suppressor gene RASSF-1α in thirty-nine women at increased breast cancer risk 55. 
Resveratrol administration for 1 month at a 5mg dose twice-daily decreased insulin resistance, 
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blood glucose levels and oxidative stress in Type 2 diabetes patients56. Although resveratrol has 
not been studied with respect to motor function in clinical trials, long-term administration (12 
month) has shown beneficial effects in Alzheimer’s disease including attenuated decline in Aβ42 
and Aβ40 and reduced matrix metallopeptidase-9 in the cerebrospinal fluid 57-58. These studies 
indicated the potential beneficial effects of resveratrol in physiological deficits with increasing 
age.  
We therefore chose to test resveratrol, for chronic dietary supplementation starting at middle age, 
to evaluate effects of long-term oral resveratrol administration on motor and cognitive deficits in 
an aging animal model. The precise molecular mechanisms of resveratrol’s effects are still being 
evaluated. However, resveratrol is a known activator of sirtuins, a class of proteins that are 
deacetylases or mono-ADP-ribosyltransferases 59-62. Resveratrol specifically activates sirtuin1 
(SIRT1), which deacetylates peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC1α) that then promotes mitochondrial biogenesis 63-64. These effects may provide 
potential benefits in tissues such as skeletal muscle that require a high mitochondrial number and 
function. Resveratrol is also known to activate extracellular signal-regulated kinases 1/2 
(ERK1/2). ERK1/2 is a signaling cascade responsive to oxidative stress and while research is 
conflicting, some groups have found activation of ERK1/2 to be protective against oxidative 
stress65-67. Our study intended to assess if resveratrol supplementation affected any of these 
pathways in our model. 
Dopaminergic system and motor function 
Basal ganglia, cerebellum and cerebral cortex are involved in maintaining motor co-ordination 68-
69. Dopamine, a catecholamine, is an important neurotransmitter that regulates multiple functions 
including movement and motor learning 70-74. Primarily, four main dopaminergic pathways have 
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been identified in the brain: the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular 75 
(Figure 1). Dopamine is synthesized from the non-essential amino acid, tyrosine, which is taken 
up via a transporter into the dopaminergic neurons. Dopamine synthesis occurs in two steps. 
First, tyrosine is converted to L-3, 4 dihydroxyphenlyalanine (L-DOPA). The enzyme tyrosine 
hydroxylase (TH) is essential and the rate-limiting enzyme in this step. TH needs to be 
phosphorylated for the tyrosine to L-DOPA reaction to occur. Dopamine synthesis is therefore 
closely modulated by TH activity. L-DOPA is then converted to dopamine by aromatic amino 
decarboxylase (AADC).  Dopamine is transported for storage to vesicles by the vesicular 
monoamine transporter 2 (VMAT2). Substantia nigra pars compacta (SNpc) and the ventral 
tegmental area  (VTA) house the majority of dopamine cell bodies in the dopaminergic system 
76. Dopamine neurons from the SNpc project to the dorsal striatum, which forms the nigrostriatal 
pathway. The nigrostriatal pathway is important for control of voluntary movement 77.  
Dopamine is released into the synaptic cleft following an action potential at the axon terminal by 
fusion of the synaptic vesicles with the plasma membrane. The released dopamine then binds to 
G-protein coupled dopamine receptors that are divided in two main subtypes; D1 and D2. D1 and 
D5 belong to the D1 receptor subtype while D2, D3 and D4 are included in the D2 subtype. 
Their classification is based on their coupling and modulation of adenylyl cyclase 75, 78. D1 
subtype of receptors activates cyclic AMP (cAMP) dependent protein kinases via stimulation of 
Gαs/olf and adenylyl cyclase 79-80 while D2 subtype couple to Gαi/o and inhibit adenylyl cyclase 
activity 81-83.   
Following its release, dopamine is rapidly taken up by dopamine transporters (DAT) that are 
present on the presynaptic terminals. This uptake maintains auto regulation of dopamine 
synthesis by increasing or decreasing the TH-mediated enzymatic reaction, in response to 
 6 
dopamine levels. Dopamine is also metabolized in the dopaminergic neurons. Monoamine 
oxidase (MAO-A) and aldehyde dehydrogenase convert dopamine into 3,4- 
dihydroxyphenylacetic acid (DOPAC). DOPAC is then converted to homovanillic acid (HVA) 
by catechol-O-methlytransferase (COMT). Dopamine can also be converted to 3-
methoxytyramine (3-MT) by COMT that is then converted to HVA by MAO-B and aldehyde 
dehydrogenase (Figure 2). The levels of these metabolites are therefore important indicators of 
the functioning of the dopaminergic system. Decline of striatal dopamine and dopamine receptor 
levels are considered to be factors influencing declining motor co-ordination with age 84-90. 
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Figure 1. Dopaminergic pathways in the brain 
DLPFC-Dorsolateral prefrontal cortex; VMPFC-Ventromedial prefrontal cortex 
Adapted from “Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical 
Applications, 4th Ed.Chapter 4. Psychosis and schizophrenia 
https://doctorlib.info/pharmacology/stahls-essential-psychopharmacology-4/4.html 
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Figure 2. Dopamine synthesis, release, uptake, and metabolism 
TH-Tyrosine hyroxylase; AADC-aromatic amino acid decarboxylase; L-DOPA-L-3, 4-
dihydroxyphenylalanine; DA- dopamine; DAT- dopamine transporter;  
MAO - monoamine oxidase; COMT-catechol-O-methyltransferase; DOPAC - 3, 4-
dihydroxyphenylacetic acid; HVA- homovanillic acid; 3-MT-3-methoxytyramine ; D1/D2- 
Dopamine receptors (1/2); DβH-Dopamine beta hydroxylase; PNMT- Phenylethanolamine N-
methyltransferase; AC-Adenyly cyclase; cMAP: Cyclic adenosine monophosphate 
 Adapted from 91 
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Obesity and dopaminergic system 
Dopaminergic system is involved in reward circuit of the brain. Intake of addictive substances 
such as cocaine causes dopamine to be released in the reward center of the brain (mesolimbic 
center including nucleus accumbens) and reinforces addictive behavior 92. Obesity is associated 
with lower levels of striatal dopamine and dopamine receptors, especially D2 93-95 which is 
postulated to lead to binge-eating to stimulate dopamine production 96-97. We therefore 
hypothesized that we would observe a similar eating behavior in our study in order for the 
animals to reach increased reward thresholds. As resveratrol has shown beneficial effects in 
aging and obesity, our goal was to probe its effects in our model using behavioral motor function 
tests and analysis of components of the dopaminergic system. 
Obesity, aging and muscle function 
 
In addition to neuronal control of motor function, muscle health plays an important role in 
maintenance of sensorimotor co-ordination. Sarcopenia, a loss of muscle strength and function 
with increasing age, exacerbates loss of balance, falls and fractures in older adults 98-99. Obesity 
adds another dimension to sarcopenia, leading to a condition known as sarcopenic obesity where 
age-related increase in bodyweight is accompanied by loss of muscle strength and function 100-
102. In a study by 103, sarcopenic obesity was shown to compound difficulties in physical 
function. Sarcopenic obesity is an important contributor to reduced mobility in older population 
104-106. Currently physical activity, aerobic and resistance training are the primary treatment 
options explored for sarcopenic obesity 102, 104. As resveratrol has shown beneficial effects on 
muscle strength and function 107-108, we aimed to address whether it may also be a potential 
therapeutic intervention for sarcopenic obesity in our model. 
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Bone, obesity and aging 
Osteoporosis or low bone mass is a concern for about half the population over the age of 50 
years and osteoporotic fractures occur in men as well although women are primarily afflicted by 
this condition 109-110. Growing evidence supports the role of obesity in deteriorating bone health 
as excess weight alters cell metabolism in bone and increases oxidative stress, thereby leaving 
obese population vulnerable to bone fractures and possibly increased mortality and morbidity 111-
114.  Previous studies have explored favorable effects of resveratrol on bone health including 
stimulation of proliferation and differentiation of cells secreting bone matrix (osteoblasts) and 
inhibition of osteoclasts, the bone resorption cells 115-117. In our study we focused on molecular 
markers of bone health including ERK1/2 and Runx2; regulators of terminal chondrocyte 
differentiation, (NF)-Κβ; an inflammatory and stress response molecule 118-119 and ERK5; 
postulated to be involved in bone remodeling 120-121. Additionally, the study also intended to 
evaluate the role of obesity and resveratrol on PPARγ, a nuclear transcription factor involved in 
regulation of bone metabolism and mass 122 and Glucose Transporter 4 (GLUT4), which plays a 
critical role in insulin-dependent glucose uptake in mature osteoblasts 123. 
Cognition, aging and obesity  
Normal aging is associated with a decline in cognitive abilities 124. Loss of cognition in the 
elderly leads to difficulty in performing day-to-day tasks. Memory and attention are some of the 
most affected aspects along with processing speed and reasoning 124-125. Evidence from 126-127 
suggests that weight gain with increasing age has a negative co-relation with multiple aspects of 
cognitive function including attention, verbal memory and speed of processing. For the purposes 
of this study, we will focus on working and spatial memory for representing cognitive defects. 
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Working memory is a complex construct that promotes retaining information for a short period 
of time for later access and manipulation. Both visual and auditory forms of information are 
assimilated as working memory 128. In a study by 129 older adults (age range: 66–79 years) 
performed significantly worse compared to young adults (age range: 22–34 years) on working 
memory task.  Working memory decline is thought to begin around middle age 130. The 
prefrontal cortex (PFC) is known to support working memory 131-132. Aging weakens the ability 
of PFC to maintain persistent firing of neurons 133 while increased bodyweight is correlated with 
deficits in working memory 134. In our study, working memory was measured using the novel 
object recognition test. It is a non-aversive test that substitutes a novel object in place of a 
familiar one and the time spent exploring the novel object is indicative of the animal’s preference 
for novelty and retention memory 135-136. The test does not require external reward or motivation 
and instead relies on the natural exploratory behavior of mice 136. 
Spatial memory is part of the cognitive system that records navigational information, and uses it 
to find a way through one’s environment 137. Studies by 138-141 have observed that spatial memory 
declines with advancing age and increase in bodyweight. To test spatial memory in our model, 
we used the novel place recognition test. Similar to novel object recognition, the animals were 
habituated with familiar objects and tested by placing one of them in a different location. Time 
spent exploring the familiar object in a novel place was used as an index to measure spatial 
memory in our model.  
Rationale and experimental design  
 
In a previous study from our lab 36 observed the onset of motor function deficits in middle-aged 
animals. Sarcopenia, dementia and osteopenia are also known to afflict the middle-aged 
population. Our study was therefore designed to initiate dietary supplementation with resveratrol 
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(120mg/kg of food; consistent with the previous study in our lab) in middle-aged male C57BL/6 
mice (13-15 months), a strain commonly used for aging studies. Obesity in the aging population 
is known to increase the risk for type 2 diabetes and cardiovascular dysfunction. In order to 
elucidate molecular and behavioral effects of resveratrol in a model of aging and obesity, our 
study consisted of three groups. 1] Control (Non-overweight) 2] Control (Overweight) 3] 
Resveratrol-supplemented (Overweight). Originally the study was designed to conclude after 10 
months, when mice reached old age (23-25 months). However due to weight gain, there was 
some attrition in the treatment groups that was attributed to increased risk of the cardiovascular 
system by the consulting veterinarian.  We therefore concluded the study at 8 months. Animals 
were allowed ad libitum access to food, which was weighed every 3-4 days to calculate an 
approximate dose of resveratrol per animal per day. The bodyweight was also recorded every 3-4 
days. Behavioral tests for motor and cognitive function were performed at 2-month intervals. In 
the study by 36, behavioral tests were conducted at 1-month intervals, however the dietary 
supplementation was short-term (2 months). For our long-term study, a 2-month interval was 
established to avoid fatigue induced by repeated testing. At the conclusion of the study, ex vivo 
muscle function tests were performed following which animals were sacrificed. Multiple tissues 
including brain, bone, spleen, muscle, heart, kidney, liver and lungs were harvested for 
molecular analysis. 
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Figure 3. Schematic of experimental design for long-term dietary resveratrol 
supplementation 
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MATERIALS AND METHODS 
Animals 
Middle-aged (13-15 month) old C57BL/6 male mice (Jackson Laboratories, Farmington, 
Connecticut) were housed (4 per cage) in the Animal Care Facility (ACF) at Duquesne 
University. The animals had ad libitum access to water and food and were maintained on a 12 h 
light: dark cycle. The study was in compliance with the Guide for the Use and Care of 
Laboratory Animals, The Institutional Animal Care and Use Committee guidelines and all 
regulations as applicable by the National Institutes of Health. 
Dietary supplementation with resveratrol 
Animals had ad libitum access to a specially formulated diet supplemented with resveratrol 
(120mg/kg) for 32 weeks. The diet (TD.10738) was custom made in small batches at Harlan 
Teklad laboratories (Madison, WI) to by adding resveratrol (TCI America, R0071) to standard 
rodent diet (Purina rodent chow).  Owing to the softer texture of TD.10738 compared to regular 
purina chow found in the ACF at Duquesne University, a control diet (TD.92708) that is 
similarly manufactured and possess comparable texture to TD.10738, was also incorporated in 
the study.  
Behavioral analysis 
A total of three behavioral tests were performed. Baseline tests were carried out at the beginning 
of the study followed by behavioral tests at 2, 4 and 6 months after the start of dietary 
supplementation. 
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Challenge beam test (CBT)      
To test fine motor co-ordination, we used the challenge beam test to measure various parameters 
of motor function. These included total number of errors and time taken to cross the beam. CBT 
was developed by (Fleming et al. 2004) after modifying traditional challenge beam tests.  The 
test consists of a Plexiglas beam (25 cm by 3.5 cm at the widest end) divided in four segments 
that get progressively narrower (0.5 cm at the narrowest end in 1 cm increments). The home cage 
of the animal to be tested is placed at the narrowest end, as motivation to traverse the beam. The 
animals are trained to cross the beam on two consecutive days for five trials each. On the third 
(test) day, a fine wire mesh (1 cm2 openings) is placed on the beam that allows for detection of 
fine sensorimotor deficits. Animals undergo five test trials, are videotaped and scored by an 
investigator blinded to the treatment. 
Spontaneous activity test (SAT) 
Animals were videotaped for 3 min in a clear Plexiglas cylinder (15.5 cm X 12.7 cm) placed on 
an elevated platform (6 inches). A mirror was placed underneath the cylinder facing the 
videotape to visualize the steps taken by the mice. The parameters measured were forelimb and 
hind limb steps, time spent grooming and rears. One rear was counted when the mouse lifted and 
placed both the front paws on the vertical glass wall and then returned to the floor. A step was 
counted when both the paws moved across the floor. Grooming was defined as the time spent by 
the animal was sitting and moved its forepaws across its face, ears or muzzle. 
Novel object and place recognition test 
Place and object recognition tests were performed over 6 consecutive days and consisted of three 
primary phases: acclimatization to the field (Day 1 and 2; 10 min per animal), exposure to 
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familiar objects (Day 3 and 4; 5 min per animal), novel object recognition (Day 5; test day; 5 
min per animal) and novel place recognition (Day 6; test day; 5 min per animal). 
1) Acclimatization 
The animals were placed on a smooth green polyvinylchloride plastic surface (45 cm × 60 
cm × 60cm) surrounded by a black box to prevent escape from the field arena. Animals were 
placed in the field for 10 min to get acclimatized. 
2) Familiarization  
On an identical surface as used in the acclimatization phase, two brackets were fixed to hold 
identical stimulus objects (saline bottles, light bulbs, mugs) on the opposite corners of the 
field. Animals were not able to displace or hide under the objects. Two dim diffuse lamps 
were used to minimize shadows from the objects. 24 hours following the second day of 
acclimatization, the animals were placed in the arena for 5 min to get familiar with the 
objects followed by the same process after 24 hours.  
3.1) Novel object recognition 
 24 hours following Day 4 (Day 2 of familiarization), the animals were placed in    the 
arena, where a novel object replaced one familiar object. The time spent by the animal 
exploring (counted when the head of the animal was 4 cm or closer to the object) was 
videotaped by an overhead JVC video camera. Objects were cleaned with 70% isopropanol 
between trials.      
3.2) Novel place recognition 
        24 hours following the novel object test, animals were tested for their spatial  
        memory using the novel place recognition test. Objects from the familiarization  
        phase were used, however, one of the objects was located in a different position  
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        (towards the center of the arena as opposed to the corners). Animals were  
        videotaped and the same criteria as novel object recognition were applied to  
        measure exploration. Both sets of videos were analyzed by an investigator  
        blinded  to the treatment. 
3.3) Exploration ratio 
         For both the tests, exploration ratio was calculated by dividing the time spent  
         by the animal exploring novel object/place by the total time spent by the animal   
         exploring both the objects. Animals that spent a total of less than 10 sec   
        exploring objects were excluded from the final analysis. 
Tissue processing 
Animals were sacrificed by decapitation at the end of 32 weeks. The following tissues were 
harvested. 
Muscle 
Following the last day of dietary supplementation, muscle function tests were performed prior to 
decapitation. The animals were anesthetized using isoflurane and sciatic nerve from the right leg 
was exposed. It was placed over two bipolar silver electrodes and stimulated by a continuous 4-
volt square-wave pulse lasting 0.1 ms. Muscle length in which maximal tension is obtained 
during a single twitch (Lo) was used for measurement. Maximum isometric tension (Po) (Po; 
stimulation frequency of 75-150 Hz) was recorded in grams, normalized to weight and used for 
further data analysis. Time to fatigue and time to peak tension under constant stimulation were 
quantified. Once the muscle test measurements were complete, skeletal muscles from the hind 
limb (gastrocnemius, EDL, TA and soleus) were dissected, weighed, snap frozen in isopentane 
cooled in liquid nitrogen and stored at -800C. Ex-vivo analysis included western blot, H&E 
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staining and immunohistochemistry. 12 μm sections, from the mid-belly of gastrocnemius, were 
cut using a cryostat, stained with H&E and observed using Olympus BX41, Infinity Analyze 
version 4.4, 400X magnification (15 random fields per mouse). All muscle analysis was 
performed in collaboration with Dr. Matthew Kostek’s laboratory, Rangos School of Health 
Sciences, Duquesne University. 
Brain 
Following decapitation, the brain was harvested, rinsed with sterile saline solution and placed in 
a mouse brain block. Prefrontal cortex, hippocampus, striatum and hindbrain were dissected. 
Prefrontal cortex, hippocampus and striatum were rapidly frozen on dry ice and stored at -800C. 
Hindbrain was fixed in 4% formaldehyde/4% NaF in phosphate buffer for 48 hours and then 
stored at 40C in 30% sucrose in 1X PBS. 
Bone 
Tibia from the left and right leg was harvested, cleaned off muscle tissue and stored as required 
for further analysis. The left tibia was snap frozen in liquid nitrogen and stored at -800C. The 
right tibia was fixed in 4% formaldehyde/4% NaF in phosphate buffer for 48 hours and then 
stored at 40C in 30% sucrose in 1X PBS.  For western blot analysis, the left tibia was pulverized 
mechanically under liquid nitrogen using a ceramic mortar and pestle. The pulverized sample 
was collected into a 6 mL plastic tube containing a 2 mL solution (2% sodium dodecyl sulfate, 
2M urea, 10% glycerol, 10 mM Tris-HCl(pH 6.8), 10 mM dithiothreitol, and 1 mM 
phenylmethylsulfonylfluoride). A TissueTearerTM was used to homogenize the suspension on ice 
in 10-15 sec of bursts. The solution was kept on ice for 30 min to allow particulate matter to 
settle, centrifuged at 15,000 rpm and the supernatant collected. The lysate was mixed with 2X 
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Laemmli buffer in a 1:1 ration and stored at -200C for further analysis. Bone analysis was 
performed in Dr. Paula Witt-Enderby’s lab with assistance from Ryan Ryland. 
Sample preparation  
Tissue (brain and muscle) was homogenized in 1X RIPA (Cell Signaling Technology, Danvers, 
MA) buffer on ice (20L /mg of tissue) using a probe sonicator. The sample was then spun down 
(40C; 10,000 rpm) and the supernatant was used for western blot analysis.  
Western blot analysis 
60g protein, as determined by Bradford protein assay, was run on a SDS-PAGE gel (8-12% as 
per the protein size) at 100V for 2 hours. The gels were transferred to a nitrocellulose membrane 
(Li-Cor Biosciences; Lincoln, NE). 5 mL of Casein blocking buffer (Li-Cor Biosciences; 
Lincoln, NE) was used to block the membranes for 1 hour at room temperature. The membranes 
were probed with respective antibodies (listed in Table 1). Following washes (3X for 10 min 
with 1XPBS+ 0.2% Tween), the membranes were incubated with secondary antibody (1: 10,000, 
Li-COR Biosciences) for 1-2 hours.  Blots were scanned using an Odyssey Imager and Li-COR 
Image Studio lite software was used for quantification and analysis. Background subtraction was 
performed using the left and right pixelated area of the bands. Quantification was performed 
using gray scale images. 
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Primary antibodies 
 
Secondary antibodies 
Antibody and Type Dilution (Product code) and 
company 
Antibody Type and dilution (Product code) and company
phospho tyrosine hydroxylase 
(pTH) 
rabbit anti phospho TH(Ser31) 
(1:1000) 
(3370), Cell Signaling, USA 
total tyrosine hydroxylase (t 
TH) 
rabbit anti total TH (1:1000) (2792), Cell Signaling, USA 
Dopamine receptor 1 (D1) rabbit anti-Dopamine D2 
Receptor (1:1000) 
(324390), Millipore Sigma, 
USA 
Dopamine receptor 1 (D2)  rabbit anti-Dopamine D2 
Receptor (1:500) 
(AB5084P), Millipore Sigma, 
USA 
Sirtuin1 (SIRT1) Rabbit anti-SIRT1 (1:1000) (2310), Cell Signaling, USA 
Voltage dependent anion 
channel (VDAC) 
Rabbit anti-VDAC 
(D73D12)mAb (1:1000) 
(4661) Cell Signaling, USA 
Peroxisome proliferator-
activated receptor gamma 
coactivator 1-alpha (PGC-1α) 
 
Rabbit anti-PGC-1, C-
Terminal (777-797) 
(1:1000) 
(516557), Millipore Sigma, 
USA 
phospho extracellular signal 
regulated kinase1/2 
(pERK1/2) 
rabbit anti-phospho ERK1/2 
(1:1000) 
(9101), Cell Signaling, USA 
total extracellular signal 
regulated kinase1/2 
(pERK1/2) 
mouse anti-total ERK1/2 
(1:1000) 
(9107), Cell Signaling, USA 
phospho extracellular signal 
regulated kinase 5(pERK5) 
 
 
 
rabbit anti-phospho 
ERK5(1:500) 
(3371), Cell Signaling, USA 
Glucose transporter 4 rabbit anti-GLUT4 (1:1000) (sc7938), Santa Cruz Biotech, 
USA 
Runt-related transcription 
factor 2 (RUNX2) 
goat anti-RUNX2 C-19        
( 1:1000) 
(sc-8566), Santa Cruz 
Biotech, USA 
NF-κB (nuclear factor kappa-
light-chain-enhancer of 
activated B cells) 
rabbit anti-NFκB(1:1000) (sc298), Santa Cruz Biotech, 
USA 
β-actin mouse anti-β-actin (1:20,000) (926-42212), Licor, USA 
Glyceraldehyde 3-phosphate 
dehydrogenase 
mouse anti –GAPDH 
(1:10,000) 
(CB1001), Millipore, Sigma, 
USA 
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goat anti-rabbit (IRDye 
680LT) 
1:20,000 (926-68021), Licor 
Biosciences, USA 
goat anti-mouse (IRDye 
800CW) 
1:20,000 (926-32210), Licor 
Biosciences, USA 
Donkey anti-goat 
(IRDye800CW) 
 1:20,000 (926-32214), Licor 
Biosciences, USA 
 
Table 1. List of antibodies used in Chapter 1 
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HPLC analysis 
HPLC was performed (Dr. Michael Zigmond’s lab, University of Pittsburgh) to determine the 
levels of dopamine and its metabolites (HVA, DOPAC) as well as the neurotransmitter 5-
hydroxytrptamine (5-HT) and its metabolite 5-hydroxyindolacetic acid (5-HIAA) in the striatum 
of control and resveratrol fed animals. Samples were weighed and homogenized (20μL of 0.1N 
PCA per mg of sample). A 20μL aliquot was analyzed by HPLC as described in Allen et al., 
2017. The mobile phase (75 mM H2NaPO4, 1.7 mM octanesulfonic acid, 25 mM Na2EDTA 
0.00001% triethylamine (v/v), and 10% acetonitrile (v/v), pH 3.0) was pumped through the 
system at a rate of 0.3 mL/min. The column was ESA C18 column (2.1×150 mm, ESA, Inc., 
Chelmsford, MA). An ESA Coulochem Model 4100A detector, an ESA Model 5010 
conditioning cell, and an ESA Model 5014B micro dialysis cell (ESA Inc., Chelmsford, MA) 
were used to detect the sample coulorimetrically. All samples were run in duplicates and 
quantified based on a series of standards with linear correlations of > 0.99997 for each 
compound (4 sets composed of 3 concentrations starting at the beginning of the run and after 
every 8th sample). 
Statistical analysis 
All statistical analysis was performed using SPSS V25. As the increase in bodyweight was a 
confounding factor, data was analyzed using ANCOVA, a modification of ANOVA that corrects 
for the confounding factor post experimental execution. Data was analyzed using a one-way or 
two-way ANCOVA with the appropriate post hoc correction as noted in respective figures. Data 
in (Figure 5C) was analyzed using one-way ANOVA followed by Dunnett’s post hoc correction. 
Statistical significance was defined at p<0.05. 
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RESULTS 
Animals on the soft pellet diet (control and resveratrol-supplemented) showed significant 
increase in body-weight 
The study was initiated with two groups of animals: control and resveratrol-supplemented. 
However, after about 4-5 weeks, we noticed a significant increase in bodyweight of the animals 
on the soft-pellet resveratrol supplemented food. As the resveratrol diet was custom made and 
differed in texture and compactness from the control diet in the ACF, we added a third group of 
mice to the study. They received a diet similar in texture and consistency to the resveratrol diet. 
As shown in (Figure 4), animals on the specially formulated soft pellet diet gained a significant 
amount of weight over the duration of the study. Weight of animals on the control and 
resveratrol soft pellet diet started significantly differing at Week 4 and Week 9 respectively from 
control animals on hard pellet diet and remained significantly higher at Week 32. This is not 
indicated in (Figure 4) to avoid cluster of significance signs. The food intake was higher for both 
the control and resveratrol fed overweight mice compared to control non-overweight mice (Table 
2) by about 2-2.2 gram/day. The percent increase in bodyweight did not significantly differ 
between the soft-pellet groups, indicating that increased food intake, not the resveratrol 
supplementation, contributed to the augmented bodyweight (Figure 4B). 
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Figure 4. Bodyweight changes between diet groups with increasing age 
Results are presented as + SEM. Bodyweight (grams) was measured every 3 days. (A) Mice fed 
the soft pellet diet gained significant bodyweight compared to their counterparts on the hard 
pellet. Resveratrol diet as hard pellet was not available in this study. (B) Percent increase in 
bodyweight compared to Week 1. Data was analyzed using two-way ANCOVA followed by post 
hoc analysis using an uncorrected Fisher’s LSD test. 
 
Weight of animals on the control and resveratrol soft pellet started significantly differing at 
Week 4 and Week 9 respectively from control animals on hard pellet diet and remained 
significantly higher at Week 32. This is not indicated in the figure to avoid cluster of significance 
signs. 
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Table 2. Average food intake of mice on soft and hard pellet diet 
Results are presented as + SEM. Food intake (grams) was measured every 3 days. Resveratrol 
diet as hard pellet was not available in this study.  n=9-17 
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Behavioral tests 
Motor function  
In this study, two types of behavioral tests were used to measure motor function deficits: 
Challenge beam and Spontaneous activity tests. 
Challenge beam test 
The test was performed according to the procedure described in Materials and Methods. Placing 
the fine wire mesh allows measurement of fine sensorimotor co-ordination. Owing to the 
significant bodyweight increase, mice were unable to navigate the 4th segment of the beam. 
Therefore, this segment was excluded from our analysis when data for all three groups was 
compiled. (Figure 5C) shows the errors for only the non-overweight control mice and includes 
errors from Segment 4. Overweight control and resveratrol supplemented animals made 
significantly more errors compared to their age-matched non-overweight counterparts (Figure 
5A). Time taken to cross the beam was not significantly different between treatment groups 
(Figure 5B). In addition to the total number of errors, other parameters including 1) errors per 
trial (Figure 5D-F) on segment 1-3 and 2) errors per segment (Figure 5G-I) at each 2-month 
interval were also assessed with no significant difference between the groups. 
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Figure 5. Overweight mice made significantly more errors on the challenge beam test than 
non-overweight mice but time taken to cross the beam was not significantly different 
Total errors made at start of the study (baseline), 2 months, 4 months, 6 months after diet 
initiation on (A) Segment 1-3 (B) Time take to cross the at start of the study (baseline), 2 
months, 4 months, 6months (C) Errors made by non-overweight mice on the entire challenge 
beam (Segment 1-4) Time to cross per trial at (D) 2 months, (E) 4 months, (F) 6 months, Errors 
per segment at (G) 2 months, (H) 4 months, (I) 6 months. Data are presented as + SEM and 
analyzed using two-way ANCOVA followed by post hoc analysis using an uncorrected Fisher’s 
LSD test (n=8-10). (Figure 5C) Data are presented as + SEM and analyzed using one-way 
ANOVA followed by Dunnett’s post hoc correction. 
# indicates compared to non-overweight age matched mice.  (# p<0.05, ## p<0.01) 
Control (Non‐overweight)  
Control (Overweight)  
Resveratrol (Overweight)  
A  B C
D  E
IG H
F
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Spontaneous activity test 
Exploratory behavior and activity were examined using the spontaneous activity test as described 
in Methods section. Animals were videotaped for 3 min in a Plexiglas cylinder and the tapes 
scored by an investigator blinded to the treatment. Four parameters were analyzed 1) Number of 
rears 2) Forelimb steps 3) Hind limb steps 4) Grooming time (Figure 6). 
There was no significant difference in number of rears, forelimb steps or grooming time between 
control and treatment times (Figure 6A, Figure 6B, Figure 6D). The number of hind limb steps 
was significantly lower in the overweight control and treatment groups compared to baseline 
(diet-matched) as well as their age-matched non-overweight counterparts (Figure 6C).  
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 Figure 6. Hind limb steps were significantly reduced with increasing age and weight gain 
 Spontaneous activity at start of the study (baseline), 2 months, 4 months, 6 months after diet        
initiation as measured by (A) number of rears (B) number of forelimb steps (C) number of hind 
limb steps (D) time spent grooming. Data are presented as + SEM and analyzed using two-way 
ANCOVA followed by post hoc analysis using an uncorrected Fisher’s LSD test (n=8-10). 
 
# indicates compared to non-overweight age matched mice.  (# p<0.05, ## p<0.01, # p<0.001)  
∞indicates compared to diet matched mice at baseline. (∞ p<0.05, ∞∞p<0.01, ∞∞∞ p<0.001) 
A  B
C  D 
Control (Non‐overweight)  
Control (Overweight)  
Resveratrol (Overweight)  
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Memory tests 
Novel object recognition 
To test if obesity with increasing age and resveratrol supplementation had an effect on working 
memory, animals were tested according to the novel object recognition paradigm. According to 
(Figure 7A), overweight mice spent significantly less time exploring the novel object compared 
to non-overweight mice while resveratrol-fed animals explored the novel object for a 
significantly longer duration compared to overweight control mice. The data indicated that 
resveratrol supplementation improved working memory in overweight mice. 
Novel place recognition 
Similar to novel object recognition, the novel place recognition test was performed to assess 
spatial memory of the animals. As seen in (Figure 7B), there is no significant difference in the 
exploration ratio of over-weight control mice compared to non-overweight control animals. 
Resveratrol supplementation did not appear to affect the time spent exploring the object located 
in a novel place.  
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Figure 7. Resveratrol diet improved novel object but not novel place recognition at 6 
months following diet initiation 
Exploration ratio plotted at start of study (baseline), 2 months, 4 months, 6 months for (A) Novel 
Object recognition test (B) Novel Place recognition test 
Data are presented as + SEM and analyzed using two-way ANCOVA followed by post hoc 
analysis using an uncorrected Fisher’s LSD test (n=8-10). 
 
# indicates compared to age-matched non-overweight mice (## p<0.01) 
* indicates compared to age-matched overweight mice on control diet (** p<0.01) 
 
 
 
 
A  B
Control (Non‐overweight)  
Control (Overweight)  
Resveratrol (Overweight)  
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Molecular changes in the tissues 
Although we did not observe changes in the behavioral tests, we examined probable molecular 
changes due to resveratrol supplementation in multiple different tissues. 
Striatum 
Resveratrol significantly increased phosphorylated/total tyrosine hydroxylase in the 
striatum 
Tyrosine hydroxylase is an important enzyme for dopamine synthesis, which catalyzes the rate-
limiting step of converting tyrosine to L-DOPA.  Tyrosine hydroxylase needs to be in its 
phosphorylated form for the reaction to occur. The levels of total and phospho tyrosine 
hydroxylase in the striatum were significantly reduced in the overweight control mice compared 
to the non-overweight control animals. Interestingly, resveratrol supplementation restored the 
levels of both phospho and total tyrosine hydroxylase in the treatment group as compared to the 
overweight control animals (Figure 8). 
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Figure 8. Resveratrol significantly increased both phosphorylated and total tyrosine 
hydroxylase in the striatum of overweight mice 
Levels of (A, B) phosphorylated tyrosine hydroxylase and (C) total tyrosine hydroxylase were 
significantly reduced in overweight control mice. (D) Representative image for Figure 8(A-C). 
Resveratrol diet significantly increased striatal phosphorylated and total tyrosine hydroxylase in 
overweight mice. Data are presented as + SEM and analyzed using one-way ANCOVA followed 
by post hoc analysis using Bonferroni’s test (n=5-7).  
 
# indicates compared to non-overweight mice (# p<0.05) 
* indicates compared to overweight mice on control diet (* p<0.05) 
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Resveratrol supplementation increased dopamine and DOPAC levels in the striatum 
The catecholamine dopamine plays a role in modulation of motor function control. As dopamine 
is converted to DOPAC and HVA, measurement of DOPAC and HVA levels is an indicator of 
the amount of dopamine synthesized. The levels of neurotransmitter dopamine and its metabolite 
DOPAC were significantly reduced in overweight control animals, indicating that obesity affects 
the dopaminergic system. Resveratrol supplementation reversed this decline of neurotransmitter 
levels in the striatum. Increase in DOPAC levels was statistically significant while increase in 
dopamine levels showed a trend towards significance (p=0.053). Levels of 5-HT and its 
metabolite 5-HIAA were unchanged by obesity or dietary supplementation in the striatum 
(Figure 9). 
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Figure 9. Resveratrol increased dopamine and DOPAC levels in the striatum of overweight 
mice 
Levels (μM) of (A) Dopamine and (B) DOPAC were significantly reduced in overweight control 
mice. Resveratrol diet significantly increased dopamine (p=0.053) and DOPAC levels in 
overweight mice (C) HVA (D) 5-HT and (E) 5-HIAA were not changed with increasing weight. 
Data are presented as + SEM and analyzed using one-way ANCOVA followed by post hoc 
analysis using Bonferroni’s test (n=5-7). 
 
# indicates compared to non-overweight mice (# p<0.05) 
* indicates compared to overweight mice on control diet (* p<0.05) 
   p=0.053 compared to overweight mice on control diet 
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Resveratrol did not significantly alter D1 or reduced D2 receptor levels in the striatum 
Dopamine is the primary ligand for dopamine receptors and they are involved in fine motor 
control, learning and cognition. Levels of the two receptors, D1 and D2, were probed by western 
blot in the striatum. There was no significant change in the D1 receptor levels however there was 
a significant reduction in D2 receptor levels in overweight mice. Resveratrol treatment was not 
able to reverse this reduction of D2 receptors in the striatum (Figure 10). 
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Figure 10. D2 but not D1 receptors were significantly reduced in overweight control 
animals 
Levels of (A) D1 receptors and (B) D2 receptors in the striatum. D2 receptors were significantly 
reduced in overweight control mice. Resveratrol did not affect D1 or D2 levels in the striatum. 
(C) Representative image for Figure 10A and 10B. Data are presented as + SEM and analyzed 
using one-way ANCOVA followed by post hoc analysis using Bonferroni’s test (n=5-7).  
# indicates compared to non-overweight mice (# p<0.05)
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Resveratrol did not significantly alter pERK1 or pERK2 levels in the striatum 
ERK1/2 is involved in neuronal protection against oxidative stress. Levels of phosphorylated 
ERK1 and ERK2 were unchanged in the striatum of overweight aged mice in both control and 
treatment groups (Figure 11). Total ERK1 and ERK2 did not significantly differ in the three 
groups. These data indicate that in the striatum, weight gain and resveratrol supplementation do 
not have an effect on the levels of ERK1/2. 
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Figure 11. Weight gain or resveratrol treatment had no significant effect on 
phosphorylated and total ERK1 and ERK2 in the striatum of overweight mice 
No significant change was observed in levels of (A) phosphorylated ERK1 (B) phosphorylated 
ERK2 and (C) total ERK1 (D) total ERK2 in overweight control or treated mice. (E) 
Representative image for Figure 11 (A-D). Data are presented as + SEM and analyzed using one-
way ANCOVA followed by post hoc analysis using Bonferroni’s test (n=5-7).  
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Prefrontal cortex 
Resveratrol increased levels of pERK2 but not total ERK1/2 in prefrontal cortex of 
overweight mice 
ERK1/2 is involved in neuronal protection against oxidative stress. As the prefrontal cortex is 
involved in memory regulation, changes in ERK1/2 were analyzed by western blot. Levels of 
pERK2 but not pERK1 were significantly lower in overweight control mice compared to non-
overweight control mice. Resveratrol supplementation increased pERK2 levels compared to the 
overweight control mice. There was no change in total ERK1 or ERK2 protein (Figure 12). 
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Figure 12. Resveratrol increased levels of phosphorylated ERK2 but not total ERK1/2 in 
the prefrontal cortex of overweight mice 
 Levels of (A) phosphorylated ERK1 (C) total ERK1 and (D) total ERK2 were not changed with 
increased weight or resveratrol supplementation. (B) phosphorylated ERK2 was significantly 
reduced in overweight control mice and this attenuation was reversed in the resveratrol treated 
overweight group. (E) Representative image for Figure 12 (A-D).  Data are presented as + SEM 
and analyzed using one-way ANCOVA followed by post hoc analysis using Bonferroni’s test 
(n=5-7).  
 
# indicates compared to non-overweight mice (# p<0.05) 
* indicates compared to overweight mice on control diet (* p<0.05) 
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SIRT1 levels were not affected by obesity or resveratrol supplementation 
Surprisingly SIRT1, a signaling pathway known to be modulated by resveratrol, and which is 
involved in improving mitochondrial metabolism and glucose homeostasis, was not significantly 
different between the three groups in the prefrontal cortex (Figure 13A).  
Resveratrol did not increase reduced voltage-dependent anion channel (VDAC) levels in 
the prefrontal cortex of overweight mice 
Mitochondrial protein VDAC controls cross talk between mitochondria and the rest of the cell by 
functioning as a gatekeeper for the entry and exit of mitochondrial metabolites and is also a key 
player in mitochondria-mediated apoptosis. Levels of VDAC, in the striatum of overweight mice 
were significantly reduced compared to their lean counterparts. Resveratrol treatment was not 
able to reverse the loss of VDAC levels in the prefrontal cortex (Figure 13B). 
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Figure 13. Effect of resveratrol dietary supplementation on SIRT1 and VDAC levels in the 
prefrontal cortex 
(A) SIRT1 levels in the prefrontal cortex were not affected by weight or resveratrol treatment. 
(B) VDAC levels were significantly reduced in overweight mice. Resveratrol supplementation 
did not affect the reduced VDAC levels in overweight animals. (C) Representative image for 
Figure 13A and 13B. Data are presented as + SEM and analyzed using one-way ANCOVA 
followed by post hoc analysis using Bonferroni’s test (n=5-7).  
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Muscle strength and function 
Muscle strength is an important contributor to motor function. Skeletal muscle function tests 
were performed as described in Materials and Methods.  
Muscle dissection weights and mean muscle force 
Skeletal muscles consist of primarily two types of fibers; slow and fast twitch. Slow twitch fibers 
are involved in building endurance while fast twitch fibers have a greater impact on daily 
activities that require a relatively quick force production such as climbing stairs or catching 
oneself from a fall.  Soleus consists of primarily slow twitch fibers while tibialis anterior and 
extensor digitorum longus are mostly made up of fast twitch fibers. The gastrocnemius is a 
mixed muscle and consists of both slow and fast twitch fibers. Analysis of these muscles would 
give a comprehensive picture of changes in muscle fiber types and their contribution to any 
differences in muscle strength tests performed on the hind limb. These muscles also primary 
contributors to movements of the hind limb and their analysis will contribute to teasing apart 
structural and histological changes between the three groups in the study. 
Muscle force, normalized to bodyweight, was significantly reduced in overweight animals. These 
data indicate that muscle function maybe compromised, as the skeletal muscles may not be able 
to support the excess bodyweight. Resveratrol supplementation did not have an effect on the 
reduced muscle force of overweight mice (Figure 14). 
There was no difference in the weight wet of hind limb skeletal muscles between the treatment 
and the control groups (Figure 15). 
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Figure 14. Weight gain significantly reduced mean muscle force normalized to bodyweight 
(A) Mean muscle force raw values (B) Mean muscle force normalized to bodyweight. 
Overweight mice had significantly reduced mean muscle force/kg of bodyweight. Resveratrol 
supplementation did not have an effect on the muscle force of overweight animals. Data are 
presented as + SEM and analyzed using one-way ANCOVA followed by post hoc analysis using 
Bonferroni’s test (n=5-7). 
 
# indicates compared to non-overweight mice (## p<0.01) 
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Figure 15. Wet muscle weight did not differ between control and treatment groups 
 
Muscle dissection weights of hind limb skeletal muscles: right and left gastrocnemius, right and 
left soleus, left tibialis anterior, left extensor digitorum longus.  Data are presented as + SEM 
(n=9-11)  
 
 
 
 
Control (Non‐overweight)  
Control (Overweight)  
Resveratrol (Overweight)  
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Molecular changes in the muscle 
Left gastrocnemius was analyzed using western blot to test the effects of obesity, aging and 
resveratrol supplementation on markers of oxidative stress and mitochondrial function.  
Resveratrol up regulated reduced levels of VDAC in overweight mice 
VDAC levels were significantly reduced in overweight mice compared to their non-overweight 
counterparts. Increased VDAC levels in the resveratrol group showed a trend towards 
significance compared to overweight control animals (Figure 16A). 
PGC1 in the gastrocnemius muscle was not affected by obesity or resveratrol treatment 
PGC1α is a downstream target of SIRT1 and similarly involved in mitochondrial metabolism. 
Increase in weight and resveratrol treatment did not cause any significant change in PGC1α 
levels in the gastrocnemius muscle (Figure 16B). 
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Figure 16. Effect of resveratrol dietary supplementation on VDAC and PGC1α levels in the 
gastrocnemius muscle 
 (A) Resveratrol supplementation increased reduced VDAC levels (p=0.066) in overweight mice. 
(B) PGC1α levels in the gastrocnemius muscle were not significantly affected by weight or 
resveratrol treatment. (C) Representative image for Figure 16A and 16B. Data are presented as + 
SEM and analyzed using one-way ANCOVA followed by post hoc analysis using Bonferroni’s 
test (n=5-7).  
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Molecular changes in the bone 
Left tibia of the mice in all three groups was used for western blot analysis. 
Resveratrol caused significant reduction in the levels of pERK5, and up regulation of 
GLUT4 and PPARγ 
Proteins important to the bone strength and function were probed in the left tibia using western 
blot. ERK1/2, ERK5 and Runx-2 are involved in regulation of osteoblast and osteoclast 
differentiation while NFKβ is an inflammatory molecule that is also important for 
osteoclastogenesis. GLUT-4 and PPARγ are mediators of insulin and glucose homeostasis in the 
bone. Resveratrol did not significantly affect levels of pERK1/2, NFKβ or Runx-2 although 
levels of NFKβ and Runx-2 were significantly lower in both the overweight groups compared to 
the non-overweight animals (Figure 17 B, C, D). Interestingly, resveratrol up-regulated the 
significantly low levels of GLUT4 and PPARγ in the overweight mice (Figure 17 E, F). Contrary 
to GLUT-4 and PPARγ, pERK5 was significantly higher in overweight control animals. This 
increase was attenuated by resveratrol (Figure 17A). 
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Figure 17. Effect of resveratrol dietary supplementation on molecular markers of bone 
health 
(A) Resveratrol significantly attenuated the increased pERK5 levels in overweight animals. (B) 
pERK1/2 was not significantly affected by weight gain or resveratrol diet. (C) (NF)-Κβ and (D) 
Runx-2 were significantly reduced in the overweight control and treated groups. (E) PPARγ and 
(F) GLUT4 levels were decreased in overweight control animals. Resveratrol supplementation 
increased levels of both (E) PPARγ and (F) GLUT4 in overweight mice. (G) Representative 
image for Figures 17(A-F). Data are presented as + SEM and analyzed using one-way ANCOVA 
followed by post hoc analysis using Bonferroni’s test (n=7-9).  
# indicates compared to non-overweight mice (# p<0.05, ## p<0.01) 
* indicates compared to overweight mice on control diet (* p<0.05, ** p<0.01, ** p<0.001) 
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Blood glucose levels 
Resveratrol did not modulate increased blood glucose levels in overweight animals 
Blood glucose levels were measured using a Freestyle Freedom monitor to assess if resveratrol 
had an effect on increased glucose levels attributed to weight gain. Due to the timing of sacrifice 
required for muscle analysis, the measurements were taken just before the animals were 
decapitated. Ideally, the assessment would be more accurate if taken at the same time with both 
pre and postprandial readings. Owing to these limitations, the readings are not conclusive. 
However, on a preliminary basis, resveratrol did not appear to modulate blood glucose levels 
(Figure 18). 
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Figure 18. Blood glucose levels were significantly elevated in overweight mice 
Resveratrol supplementation did not affect significantly increased blood glucose levels in 
overweight mice. Data are presented as + SEM and analyzed using one-way ANCOVA followed 
by post hoc analysis using Bonferroni’s test (n=9-17). 
 
# indicates compared to non-overweight mice (## p<0.01) 
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Figure 19. Schematic of proposed changes due to weight gain and resveratrol 
supplementation in the brain, bone and skeletal muscle 
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DISCUSSION 
Gain in bodyweight as a confounding factor 
The gain in bodyweight was a result of an unexpected confounding factor. Mice on the 
resveratrol diet started gaining bodyweight around Week 4 (Figure 4). The resveratrol diet was 
specially formulated at Harlan Teklad laboratories by incorporating resveratrol powder in mouse 
purina chow that was used as the control diet. The caloric value of both the diets is similar with 
the comparable percentage of calories derived from protein, fats and carbohydrates. The diets 
differed in texture and hardness; the pellets of resveratrol diet were much softer and crumbled to 
powder easily. No instrumental analysis was used to distinguish these differences; they were 
based on manual inspection only. The reason for this difference was the custom manufacture of 
resveratrol diet without external heat application, on smaller machines and using less compaction 
force as compared to traditional purina chow. Food was provided ad libitum and weighed every 
third day to determine the total amount of resveratrol ingested by the animals. During the course 
of the study, we observed that animals on resveratrol diet ate around 2 grams/day more than 
those on control purina chow. One hypothesis was that resveratrol was causing an increase in the 
bodyweight however available literature on resveratrol did not support this conclusion 142-143. An 
alternative explanation was increase in the amount of food eaten per day could be a contributing 
factor to the weight gain. To address this question, we included a third group of animals on a diet 
similar in texture and hardness of pellet to resveratrol diet but excluding the active ingredient. 
Due to technical and funding limitations, we could only acquire one additional set of animals and 
commence dietary supplementation after completion of the first study (control mice on hard 
pellet and resveratrol treated mice on the soft pellet). Possibly due to acquiring animals at a 
different time, the third set of animals, although belonging to the same species, came from a 
 55 
different cohort and started at a lower bodyweight than the first two (Figure 1A). To address this 
issue, increase in percent bodyweight was calculated; the percentage was very similar in the two 
groups on the soft pellet diet (Figure 1B) over 32 weeks. Originally, our study was aimed at 
evaluating motor and cognitive deficits in an aging model. However, due to the increased 
bodyweight, an additional facet of obesity was introduced. Diet based obesity studies have 
generally used a high fat diet 144-145. Compared to around 26-27% of calories obtained from fats 
from the diet in our study, high fat diets generally are formulated to provide around 60% of the 
total calories from fatty ingredients like lard, beef tallow or coconut oil 146-147. Though these diets 
induce obesity in rats and mice quickly for a rapid screening of compounds, a diet supplying 
60% calories from fats would probably represent an extreme case in humans. Obesity in humans, 
in general, results from increased eating and a decline in physical activity 148. In our model, 
weight gain was affected by an increase in food intake rather than a formulated high fat diet. 
Thus our model may provide a good representation of obesity induced due to overeating. 
Resveratrol has shown beneficial effects in obesity models using a high-fat diet 149-150. To the 
best of our knowledge, our study is the first to probe the effects of resveratrol in an aging and 
overeating-induced obesity model. 
Previously our lab found that oral resveratrol administration for 2 months showed improvement 
in motor function deficits in old mice 36. To test whether dietary supplementation starting at 
middle age halts the onset of motor and cognitive deficits, mice were fed a diet supplemented 
with resveratrol at around 13-15 months of age. As the treatment group started unexpectedly 
gaining weight, a third group on a control diet, similar in texture and pellet hardness to the 
resveratrol diet was added to the study. To the best of our knowledge, these data are the first to 
probe changes due to simply over-eating of food without addition of any high fats/sugar. These 
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data are important as with an increasing sedentary lifestyle, the incidence of obesity is on the 
rise. Obesity, especially in older adults is co-related with a decline in motor and cognitive 
function 151. Not only are overweight individuals prone to health issues including hypertension, 
diabetes, heart disorders, 152 they also have lower life expectancy compared to non-overweight 
individuals 153.  Obesity is associated with poor cognition 154-155 and motor function deficits 156-
157 with increasing age.   
Obesity studies, for the most part, use high-fat diets to induce excess weight gain 158-159. While 
the differences between overeating of normal food vs. a high fat diet were beyond the scope of 
this study, the results from these experiments elucidated behavioral and molecular changes 
induced by excessive eating in aging mice. This study could be used as a preliminary model for 
how overeating of regular food induces changes in the body that may, in part, be similar to eating 
a high-fat diet. 
Motor function tests 
To study the motor function deficits, the challenge beam test was used, as it is an indicator of 
fine motor co-ordination 160. However, due to the excessive weight gain, the animals were unable 
to correctly traverse the narrowest segment (4th) of the beam, especially towards the end of the 
study. They often dragged themselves across the segment, thereby rendering the analysis of 
motor function deficits on this part of the beam inconclusive. Nevertheless, analysis of the first 
three segments showed that overweight mice made significantly more errors than the non-
overweight animals and resveratrol treatment did not affect these errors. There was no significant 
difference in the time taken to cross the beam. This parameter is measured as the time taken to 
walk only when the animal is taking a forward step and excludes any amount of time that the 
animal is stationary and/or grooming on the beam.  Although the overweight control and 
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resveratrol treated mice had difficulty walking across due to their weight, the total time as 
measured by forward steps did not significantly differ from the non-overweight animals.  
It is possible that resveratrol did not improve motor function in this model; however, the dose of 
resveratrol (120mg/kg of food) used in this study was decided based on 36, where the study was 
not confounded by overeating induced weight gain. It is possible that a higher dose would be 
necessary to effect a behavioral change. Additionally, a test that is not affected by weight (gait 
walking) may offer a better measure of motor function in our model. 
There was no significant alteration in the parameters measured for the spontaneous activity test 
(rears, number of forelimb steps and grooming time). These data indicate that aging, obesity and 
resveratrol treatment did not affect the exploratory activity of the animals (as measured by rears). 
This was a surprising observation as the rears are mediated, in part, by dopamine 
neurotransmission 161-163. Levels of dopamine were low in overweight control group. Possibly, 
the excess weight mediated another signaling pathway or the animals were motivated to explore 
for food due to their increased appetite. The number of hind limb steps was significantly reduced 
in the overweight animals. As the excess weight was concentrated around the mid-section of the 
mice, it may be the contributing factor to the animals’ lethargic hind limb movements. 
Cognition and memory tests 
Novel object and place recognition tests were performed to assess learning and memory in our 
animal model. Aging and obesity are both risk factors for memory loss 164-167. One of the aims of 
this study was to test if resveratrol supplementation improves cognitive loss associated with 
obesity and aging. We found that working memory as measured by novel object recognition was 
impaired in overweight control animals. However, the test paradigm followed resulted in a 
caveat. As seen in (Figure 7A), the exploration ratio for the overweight mice was less than 50%, 
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indicating that the mice spent more time exploring the familiar object. If the mice had truly 
impaired memory, they would be spending an equal amount of time exploring both familiar and 
novel objects, as they would not remember the introduction of the novel object of a different 
shape on the test day. More time exploring the familiar object indicates that they could prefer the 
shape of the familiar object more than that of the novel object and hence does not give us a true 
indication of the state of working memory in these animals. The novel place recognition is a 
better indicator of memory, as it involves the same objects and therefore no bias is introduced 
towards a different shape.  
We did not observe a significant difference in the spatial memory function as measured by novel 
place recognition following resveratrol diet. One conclusion is that resveratrol did not affect 
spatial memory in these animals. However, the design of the test was such that the spatial 
memory was tested 48 hours following the familiarization phase. Although, animals were 
familiarized for two consecutive days, 48 hours is a long time for retention of spatial placement 
of the objects. A more robust paradigm would be to test the mice within a few hours of the 
familiarization phase. The results from such a study design would offer more conclusive data 
regarding memory loss and the effect of resveratrol on cognition in our model. 
In spite of not observing significant behavioral changes, different regions of the brain, muscle 
and bone were probed to detect molecular changes caused by overeating and resveratrol dietary 
supplementation. 
Brain 
Striatum 
As motor function with aging was one of the primary aims of this study, levels of phosphorylated 
and total tyrosine hydroxylase were measured. Tyrosine hydroxylase, part of the dopaminergic 
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system, is an important enzyme in the dopamine synthesis pathway. Interestingly, both phospho 
and total tyrosine hydroxylase levels were significantly reduced in aged overweight mice. These 
results agree with studies by 168, where tyrosine hydroxylase mRNA expression was significantly 
reduced in the dopaminergic region of high-fat diet fed C57Bl/6 mice and findings of 169 
showing reduced TH+ immunoreactivity in the substantia nigra of high-fat diet fed mice. 
Although we were not able to analyze the errors on all the segments of the challenge beam test 
and therefore conclusively determine motor function deficits, increased bodyweight has been 
shown to correspond to decreased motor co-ordination and increased injuries due to falls and 
balance problems. 169-170. Even discounting the fourth segment, overweight mice made 
significantly more errors on the first three segments of the beam than non-overweight mice.  
Studies have shown that food and drugs (such as cocaine) exert their rewarding properties party 
by activation of the mesolimbic system 93. Chronic drug abuse or excessive food consumption 
may cause overstimulation of the dopamine receptors and can result in their down regulation. D1 
receptors are recycled and can return to the cell surface to bind ligands while D2 receptors are 
degraded by G protein coupled receptor-associated sorting protein (GASP) in the lysosomes 171-
172. The difference in the mechanism of action of D1 and D2 receptor endocytosis could serve as 
one possible explanation for the data seen in this study. 
Resveratrol treatment did not affect the reduced striatal D2 receptor levels. Dopamine levels in 
the whole tissue were increased in the treatment group although they did not reach statistical 
significance; the p value was very close to 0.05 (p=0.066). These data indicate that resveratrol 
could be modulating dopamine levels, possibly by increasing the levels and activity of tyrosine 
hydroxylase. In this study, resveratrol did not appear to affect dopamine receptor levels. Levels 
of serotonin (5-HT) and its metabolite 5-Hydroxyindoleacetic acid (5-HIAA) were also 
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measured in the control and treatment group. Interestingly, there was no change in striatal 5-HT 
and 5-HIAA.  This is contrary to previous studies that have found higher levels of 5-HT in lean 
groups of dogs 173 as well as induction of hyperphagia and obesity in rats with depleted serotonin 
174. It is possible that in C57BL/6 mice, dopamine modulation affects weight and appetite to a 
greater extent than serotonin. 
Levels of phospho and total ERK1/2 were also measured in the striatum. Studies by 175-176 have 
shown that H2O2 mediated activation of ERK1/2 plays a critical role in cell survival rat PC12 
cells and primary cortical neurons against oxidative stress. In addition, considering the weight 
gain in our model, probing ERK1/2 in the brain was significant as the hormone inhibiting 
hunger, leptin, has been shown to activate ERK pathway 177-178. In this model, we hypothesized 
that due to over-eating, the leptin regulation was likely impeded and therefore ERK activation 
would be reduced in the overweight animals. However, there was no significant difference in the 
levels of phospho and total ERK between the three groups. Leptin is also known to modulate 
other signaling pathways AMPK, PI3K, mTOR, STAT3, STAT5 177 which could possibly be 
involved and future studies could probe for their regulation in this model. 
Prefrontal Cortex (PFC) 
In addition to the striatum we also probed the PFC for different markers including ERK1/2, 
VDAC and SIRT1, the signaling pathway known to be activated by resveratrol 64, 179. There are 
mixed reports on the effect of resveratrol on ERK1/2 activation; in prostrate and renal carcinoma 
cells resveratrol has been shown to inhibit ERK1/2 180-181 while it has been shown to activate 
ERK1/2 in a model of chronically stressed rats 182, in rats facing cognition impairment due to 
unpredictable mild stress 183 and in mice subjected to forced swim and tail suspension test that 
induces depression 184. In our model, to further narrow down the signaling mechanisms, we 
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looked at ERK1 and ERK2 separately. Interestingly, while there was no significant change in 
levels of pERK1, pERK2 was reduced in overweight animals. Resveratrol fed animals showed a 
significant increase in levels of only pERK2 while total protein remained constant across all 
groups. These data indicate that ERK1 and ERK2 are differently regulated and possibly perform 
varying roles. While these disparities were not further explored in this dissertation, investigation 
of differing ERK1 and ERK2 roles in future experiments will provide a greater insight in the 
function of these proteins. We were unable to probe for ERK5, another member of the MAPK 
family that is also known to play a neuroprotective role (Cavanaugh 2004), in the striatum, PFC 
and muscle as the anti-ERK5 (Table 1) antibody was undetectable in these lysates. 
We also probed for SIRT1 levels in the prefrontal cortex. Not only is resveratrol a well-known 
SIRT1 regulator but SIRT1 is down regulated by a high-fat diet 185-188 and its levels decrease 
with increasing age187-189. Surprisingly, there was no significant difference between SIRT1 levels 
in all three groups although SIRT1 in non-overweight mice was slightly higher. Given the 
available literature on resveratrol’s modulation of SIRT1 190-192, we expected to observe a change 
in SIRT1 levels at least in the overweight resveratrol group. One possible reason for these 
observations is that SIRT1 activation by resveratrol may require additional factors. A study by 
193 showed that lamin A is important for SIRT1 activation by resveratrol. We can speculate that 
due to obesity and increasing age, some critical factors for SIRT1 activation maybe missing or 
present in amounts low enough to not support SIRT1 activation. A more exhaustive study 
including investigative analysis of such factors may provide a viable explanation for our 
observed data. 
In addition to signaling pathways, we also probed for proteins involved in the mitochondrial 
function. Mitochondrial dysfunction is a hallmark of the aging brain 194-197. Additionally, obesity 
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has also been shown to impair mitochondrial function 198-199. We probed for VDAC in the brain 
and gastrocnemius muscle (discussed in the next section). The trends for both the tissues were 
similar; VDAC was low in overweight mice and the levels increased in the treatment group.  
Muscle  
A rise in oxidative stress levels with increasing age damages skeletal muscle 200-201, contributing 
to motor function deficits. In our study, in addition to evaluating changes in the brain, we also 
investigated functional and molecular changes in the skeletal muscle. There was no significant 
difference in the wet weight of any of the muscles (gastrocnemius, TA, EDL, soleus).  This was 
a surprising observation as we expected some atrophy of muscles to be associated with the 
increased bodyweight on account of decreased activity (less hind limb steps as seen in the 
cylinder test). Previous studies 202-204 have observed that muscle weights are reduced in obese 
mice compared to lean mice. However, our data indicated that the hind limb muscles might not 
be able to support the increased bodyweight and as a result produce less overall muscle force. 
This hypothesis was validated in the strength tests where muscle force was reduced in the 
overweight groups, with resveratrol having no effect on this parameter. At the time of writing 
this dissertation, further tests are underway in Dr. Matthew Kostek’s laboratory including muscle 
fiber typing and measuring cross sectional area of individual muscle fibers to examine for any 
abnormal shape or inflammation.  
In addition to muscle strength tests, we also probed for changes at a molecular level; VDAC, a 
measure of mitochondrial function, and PGC1/SIRT1 pathway that is known to be important 
for resveratrol activity 179, 205. VDAC was significantly reduced in the overweight control group 
indicating that either mitochondrial number or function or both are possibly compromised with 
excess weight gain. Our results agree with other studies showing mitochondrial dysfunction with 
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obesity 206-209. While resveratrol treatment did not significantly increase VDAC levels, the p 
value trended towards significance (p=0.066). Future studies probing mitochondrial biogenesis 
and other protein markers (cytochrome c) will provide further insights into resveratrol’s effect on 
skeletal muscle bioenergetics.  
Contrary to our hypothesis, we did not see a significant change in PGC1 levels in the 
gastrocnemius. We also probed for SIRT1 but for an unknown reason, we were unable to 
visualize this protein in gastrocnemius.  However, levels do not indicate the functional state of 
PGC1. SIRT1 deacetylates PGC1, which then regulates energy metabolism in skeletal muscle 
63, 210-211. Probing for deacetylated PGC1 210 will be a more reliable indicator of resveratrol’s 
effect on this particular pathway. 
Bone 
Molecular markers were also probed in left tibia, as resveratrol is known to improve age-related 
bone loss 212-213 as well as bone health in obesity 214-216. We observed a significant reduction of 
PPARγ levels and GLUT4 receptors in overweight control animals consistent with studies by 217-
218. Resveratrol increased both PPARγ levels and GLUT4 receptors in the treatment group 
indicating a potential hypoglycemic effect in the treatment group 219. However, there was no 
significant reduction in blood glucose levels in both the overweight groups. The measurements 
were taken just before sacrificing the animals due to the design of the experiment. A more 
controlled pre and postprandial blood glucose level would be a better measure however it is 
possible that the increased glucose uptake (not specifically measured) was not enough to affect 
the blood glucose levels. Taken together our results indicate that resveratrol diet exhibited 
positive molecular changes in bone health of overweight mice. Interestingly, resveratrol inhibited 
pERK5 that was significantly increased in the tibia of overweight mice. There exist conflicting 
 64 
reports of MEK5/ERK5 pathway in bone health. A study by 220 has shown MEK5 to inhibit 
osteoblast differentiation, an important pathway for bone remodeling while 120 and 121 have 
shown ERK5 to be important for osteoblast and osteoclast differentiation respectively. During 
the course of our study, we collected the right tibia for further bone strength tests. The finding 
from these studies will be pertinent to determine the role of MEK5/ERK5 in our model. We 
found no difference in pERK1/2 while Runx-2 was significantly attenuated in both the 
overweight groups indicating that an increase in bodyweight reduced the chondrocyte and 
osteoblast differentiation, thereby possibly weakening bone strength 221. Resveratrol did not have 
an effect on its levels. Surprisingly, (NF)-Κβ levels were reduced in the overweight groups. We 
expected (NF)-Κβ to be reduced in the resveratrol group on account of its antioxidant and anti-
inflammatory properties but not in the overweight control group. Obesity has shown to be an 
activator of the (NF)-Κβ 222-223. However, in the bone, (NF)-Κβ is also an important regulator of 
osteoclast differentiation 224. Deletion of (NF)-Κβ resulted in a complete deficiency of 
osteoclasts 225 that can result in osteopetrosis, an abnormal hardening of bones 226. A more 
comprehensive analysis of upstream regulators of (NF)-Κβ including receptor activator of 
nuclear factor kappa-Β (RANK) and its ligand (RANKL) 227 combined with results from bone 
strength tests will provide a better understanding of the regulation of bone metabolism in our 
model. 
Comparison with previous studies in Cavanaugh lab 
A previous study in our lab examined the effects of short-term (2 month) dietary 
supplementation with natural antioxidants including resveratrol, its analogue (pinostilbene) and 
wild blueberry on age-related motor functions. Both resveratrol and wild blueberry 
supplementation attenuated motor function deficits (Allen, E., 2013, The effect of L-dopa and 
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natural products on age-related motor deficits and dopaminergic cell survival, Duquesne 
University, Pittsburgh, PA). Resveratrol activated neuroprotective pathways ERK1/2 in the 
striatum but dopaminergic markers including dopamine, DOPAC and tyrosine hydroxylase were 
unaltered.  In our long-term study resveratrol did not show improvement in motor function 
deficits following chronic administration, possibly due to the weight gain that resulted in a lower 
dose per animals compared to the short term study. Chronic resveratrol supplementation also 
increased levels of total and phosphorylated tyrosine hydroxylase, dopamine and DOPAC 
attenuated by weight gain. These data indicate that long-term resveratrol diet maybe affecting 
synthesis of tyrosine hydroxylase, which may then result in an increase in dopamine levels 
(Figure 2). We did not observe activation of ERK1/2 in the striatum however attenuated pERK2 
levels in the prefrontal cortex were significantly increased; further indicating that resveratrol 
exerts differential effects depending on specific brain regions, duration of administration and 
dose. We also observed changes in molecular markers of glucose homeostasis and cellular 
differentiation in the bone that were not examined in the short-term study. Taken together, our 
data indicates that chronic resveratrol dietary supplementation may affect modulation of the 
dopaminergic system and a dose corrected for bodyweight may show improvement in motor 
function decline similar to that observed in the short-term study. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Our data suggests that prolonged resveratrol supplementation can potentially induce molecular 
changes that may prove beneficial for combating physiological decline with increasing age and 
bodyweight. Although we did not observe any significant behavioral changes, it is possible that a 
higher dose is needed to effect these changes. The dose used in our study was based on 36 and did 
not account for the increased bodyweight introduced as a confounding factor in our experiments. 
Future studies will be conducted with a dose corrected for increased bodyweight. It will also be 
interesting to compare and contrast our model to current obesity models that use a high-fat diet in 
terms of molecular and behavioral changes. An exhaustive analysis of fat content and type 
(brown vs. white), cholesterol levels, changes in cardiovascular, renal and hepatic systems will 
prove instrumental in further characterization of our model. Finally, addition of an exercise 
component to the study will be allow us to gauge combined effects of natural antioxidant 
supplementation and physical activity on overall health and function with advancing age.   
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CHAPTER TWO 
 
Neuroprotective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells 
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INTRODUCTION AND RATIONALE 
Several genetic, molecular, and cellular mechanisms leading to oxidative stress, mitochondrial 
dysfunction, and apoptosis have been shown to contribute to dopamine (DA) neuronal 
dysfunction and its loss with normal aging and neurodegenerative diseases like Parkinson’s 
disease (PD) 228-234. However, the underlying mechanisms remain elusive. Till to date no drug 
therapy is available to halt the progressive loss of DA neurons that occurs in the aging brain. 
In humans, basal oxidative stress and oxidative damage are higher in the substantia nigra pars 
compacta (SNpc), a region rich in dopaminergic neurons, as compared to other areas of the brain 
235. It is thought that this may be due, in part, to the autoxidation of DA leading to the formation 
of reactive oxygen species (ROS) and reactive nitrogen species (RNS), dopamine-quinone 
species, superoxide radicals, and hydrogen peroxide 236-238. Studies have also shown that toxin-
induced oxidative stress causes nigral cell degeneration 239-242. Moreover, an increase in 
oxidative stress, as indicated by increases in lipid peroxidation, protein and DNA oxidation has 
been observed in the aged brain and PD patients 243-248.  Therefore, devising therapeutic 
interventions that can lead to the reduction in oxidative stress in DA regions are of extreme 
importance.  
Resveratrol (trans-3, 5, 4-trihydroxystilbene), a polyphenolic compound that is present in many 
dietary sources, such as grapes, red wine, and peanuts possess antioxidant, anti-inflammatory, 
and anti-apoptotic properties 242, 249-251. Resveratrol has been shown to protect DA neurons 
against several toxins, including 1-methyl-4-phenyl pyridinium (MPP+), 6-hydroxydopamine (6-
OHDA), and lipopolysaccharide (LPS) 240-242, 252. However, the oral absorption of resveratrol is 
extremely low due to rapid and extensive metabolism resulting in only trace amounts of 
unchanged resveratrol in the systemic circulation 253-255, limiting its therapeutic potential. It is 
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therefore necessary to explore analogs of resveratrol that show similar protective effects but 
circumvent rapid biotransformation. 
Piceid (3, 5, 4’-trihydroxystilbene-3-O-β-D-glucopyranoside), or polydatin, is a stilbenoid 
glucoside and a resveratrol precursor (glycoside form of resveratrol) found in grapes and red 
wines 256. Piceid retains the biological properties of resveratrol but is less susceptible to 
enzymatic oxidation. Similar to resveratrol, piceid has been shown to have antioxidant 257 and 
anti-inflammatory properties 258. Previous studies have shown that oral administration of piceid 
results in high levels of resveratrol in vivo and increases the amount of trans-resveratrol available 
from the diet 259. Further, piceid has been shown to exhibit higher scavenging activity against 
hydroxyl radicals than resveratrol in vitro 260.  However, it is not known whether piceid has the 
ability to defend dopaminergic cells against oxidative stress. 
To understand the underlying mechanism of neuroprotection, it is important to examine cell-
signaling pathways that play a role in neuronal survival.  Extracellular signal-regulated kinases 
ERK1/2 and ERK5 are two prime members of the mitogen-activated protein kinase (MAPK) 
family of proteins and are considered important for the neuronal survival against oxidative stress 
261-263. ERK1/2 and ERK5 are known to increase the survival of DA neurons under basal 
conditions 264 and following neurotoxin-induced oxidative stress 263, 265. Further, modulation of 
these signaling pathways is observed in dopaminergic brain regions during postnatal-
development and aging 265-266. This study examined the effects of piceid on DA-induced cell 
death and ERK1/2 and ERK5 signaling pathways in human dopaminergic-like SH-SY5Y cells. 
To the best of our knowledge, this is probably the first report indicating a possible regulatory 
role for piceid on ERK activity. Our data suggest that piceid protects SH-SY5Y cells against 
DA-induced toxicity and the protective effect of piceid is mediated via ERK activation. Piceid 
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pretreatment also reduced caspase-3/7 activity and increased the expression of Bcl-2, suggesting 
that piceid inhibits apoptosis induced by DA. 
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MATERIALS AND METHODS 
Cell Culture 
Undifferentiated, low-passage (P3-P10) human dopaminergic neuroblastoma cell line, SH-
SY5Y, was cultured in Dulbecco's Modified Eagle's medium (DMEM, Cat. No. 11965-084, Life 
Technologies) supplemented with 10% (v/v) fetal bovine serum (Cat. No. S11550, Atlanta 
Biologicals, Atlanta, GA), 0.05 units/ml penicillin, and 0.05 mg/ml streptomycin (Cat. No. 
P0781, Sigma-Aldrich, St. Louis, MO) and maintained at 37ºC in a humidified 5% CO2 
atmosphere. Cells were plated at a density of 6.0 x 106 cells per 35mm plate or 1.5 x 104 cells per 
well in 96 well plates 48 hr before treatment. Cell culture reagents, unless otherwise noted, were 
purchased from Sigma-Aldrich. 
DA treatment  
DA (Cat. No. H850, Sigma Aldrich) was dissolved in sterile water to an initial concentration of 
100mM. The DA solution was further diluted with sterile water to the required concentration. 
Concentration-dependent toxicity of DA was determined by treating SH-SY5Y cells with 50, 
100, 150, and 200µM for 12 hr. The 150µM concentration of DA which caused ~50% loss of 
cell viability at 12 hr, was used for subsequent experiments with piceid and/or kinase inhibitor 
pretreatment. 
Piceid treatment 
Piceid was purchased from TCI America (CAS Number: 27208-80-6). A stock solution of piceid 
was dissolved in Dimethyl sulfoxide (DMSO, Sigma Aldrich). For each treatment, a fresh 
dilution of piceid was made in serum-free media. Several pilot experiments were conducted to 
determine the optimum dose of piceid that could protect SH-SY5Y cells against DA-mediated 
toxicity. In our preliminary experiments, we found that a dose lower than 10μM and higher than 
30μM was not able to significantly attenuate dopamine-induced toxicity in SH-SY5Y cells 
 72 
(Figure 21B). Therefore, cells were pretreated with 10, 20, and 30µM dose of piceid for 1 hr 
prior to exposure to DA. After several experiments, 30µM piceid was used for further 
experiments, as this dose was found to be most effective in protecting SH-SY5Y cells against 
DA-mediated toxicity.  DMSO was used as a vehicle control. 
U0126 or XMD8-92 inhibitor treatments 
To block phosphorylation of ERK1/2 or ERK5, SH-SY5Y cells were treated with U0126 (10 
µM; Cat. No. 662005, Calbiochem, San Diego, CA) or XMD8-92 (10 µM, Cat. No. 4132 Tocris 
bioscience, Bristol, UK), respectively, 1 hr prior to piceid (30μM) treatment for different time 
points. DMSO was used as a vehicle control. 
Cell viability assays 
Cell viability was determined using two different viability assays i) CellTiter-Glo® Luminescent 
Assay (Cat. No. G7570, Promega Inc., Madison, WI) and ii) dead cell protease assay (Cat. No. 
G7570, Promega Inc., Madison, WI).  For both assays, cell viability was measured in a black, 
clear-bottomed 96-well plate (Cat. No. 3603, Corning Inc.) according to manufacturer’s 
instructions. Luminescence was measured on a microplate reader (Victor3 1420 multilabel 
counter, PerkinElmer, MA). 
Caspase-Glo® 3/7 Activity Assay 
The activity of caspase-3/7 was detected in 96-well (Cat. No. 3603, Black plate with clear 
bottom, Corning Incorporated) format using the Caspase-Glo® 3/7 assay (Cat. No. G8091, 
Promega Inc.) per the manufacturer’s instructions. Briefly, 100µL of the Caspase-Glo 3/7 
reagent were added to each well containing 100µL of media and cells. The contents of wells 
were gently mixed using a plate shaker at 300-500 rpm for 30 sec. The plate was then incubated 
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at room temperature for 1 hr. Luminescence was measured on a microplate reader (Victor3 1420 
multilabel counter, PerkinElmer, MA). 
Cell lysis collection for western blot analysis 
Cell lysates were collected using lysis buffer containing 20mM Tris, pH 6.8, 137mM NaCl, 
25mM β-glycerophosphate, pH 7.14, 2mM NaPPi, 2mM EDTA, 1mM Na3VO4, 1% Triton X-
100, 10% glycerol, 5μg/ml leupeptin, 5μg/ml aprotinin, 2mM benzamidine, 0.5mM DTT, and 
1mM PMSF. Cell lysates were centrifuged at 11,000 rpm for 30 min at 4ºC and the supernatant 
was collected and stored at -80ºC until used for western blot analysis. 
Western blotting 
Total protein content was assessed by Bradford Bio-Rad protein assay (Cat. No. 500-0006, Bio-
Rad, Hercules, CA) and 30μg of protein was detected using 8% SDS-PAGE for phosphorylated 
and total ERK1/2 and ERK5 proteins, and 12% SDS-PAGE for Bcl-2 protein. After running the 
samples, gels were transferred to a nitrocellulose membrane (Cat. No. 926-31092, Licor 
Biosciences, Lincoln, NE). The membranes were washed for 5 min with 1X PBS and blocked for  
1 hr in a Casein Blocking Buffer (CBB, Cat. No. 927-40200, Licor Biosciences) at room 
temperature. Membranes were then incubated overnight at 4ºC in primary antibody in CBB with 
0.2% Tween-20. Antibodies included rabbit anti-phospho-ERK1/2 (Dilution–1:1000, Cat. No. 
9101, Cell Signaling, Beverly, MA), mouse anti-total ERK1/2 (Dilution–1:2000, Cat. No. 9107, 
Cell Signaling), rabbit anti-total ERK5 (Dilution–1:1,000, Cat. No. 3372, Cell Signaling), and 
rabbit anti-total Bcl-2 (Dilution–1:1000, Cat. No. 2876S, Cell Signaling). Mouse anti-α-Tubulin 
(Dilution-1:10,000, Cat. No. T5168, Sigma–Aldrich) was used as a loading control. After 
incubation with primary antibody, blots were washed in 1X PBS solution with 0.2% Tween-20 
(1X PBS-T) and incubated with goat anti-rabbit (Dilution–1:20,000, Cat. No. 926-68021, Licor 
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Biosciences) and goat anti-mouse (Dilution–1:20,000, Cat. No. 926-32210, Licor Biosciences) 
secondary antibodies for 1hr at room temperature. After washing the membranes with 1X PBS-
T, the protein bands were visualized on an Odyssey Infrared Imager and quantified with Odyssey 
software (Licor Biosciences). 
 Statistical analysis 
GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis. Data are 
expressed as mean ± SEM. For viability studies, statistical significance was determined by one-
way ANOVA followed by the Dunnett post hoc test. Statistical significance was defined at p< 
0.05 
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RESULTS 
Piceid attenuated DA-induced cell death in SH-SY5Y cells 
Chemical structures of resveratrol and its analog piceid are shown (Figure 20). SH-SY5Y cells 
were treated with increasing DA concentrations (100-250µM) for 12 hr to induce toxicity. A 
dose-dependent loss in cell viability, as measured by ATP levels, was noted following DA 
treatment with a 50% loss of cell viability following treatment with 150µM DA (Figure 21A, 
21B, 21C). Similarly, an increase in dead-cell protease activity was observed following 150µM 
DA treatment (Figure 21D) indicating cell death. Pretreatment with piceid (10-30μM) 
significantly decreased the DA-induced loss of cell viability as measured by significant increase 
in ATP levels (Figure 21B, 21C) and reduction in dead-cell protease activity (Figure 21D). As 
30μM piceid showed the maximum protection, we chose this dose for subsequent experiments. 
These data undoubtedly suggested that piceid attenuates DA-induced cell death in SH-SY5Y 
cells. 
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Figure 20. Chemical structures of piceid and resveratrol 
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Figure 21. Piceid (RV8) protects against DA-induced toxicity in SH-SY5Y cells 
(A) Concentration-dependent loss of cell viability in SH-SY5Y cells. Cells were treated with 0-
250μM of DA for 12 hr. For (B) (C) and (D) SH-SY5Y cells were pretreated with indicated 
concentrations of RV8 (1 hr) with or without DA. Cell Titer Glo (B,C) and Dead-protease 
fluorescence (D) were used to measure ATP levels and dead-cell protease levels, respectively. 
Each experiment was performed 3 independent times and data is presented as mean ± standard 
error of mean. Statistical analysis was applied using one-way ANOVA followed by Dunnett's 
post hoc test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  # indicates compared to vehicle 
while * and n.s. indicates compared to 150μM DA. 
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Piceid activates pro-survival proteins ERK1/2 and ERK5 in SH-SY5Y cells  
SH-SY5Y cells were treated with 30μM piceid at different time points (5, 10, 15, 30, 60, 120 
min, 12 hr and 24 hr) to study possible regulatory role for piceid on ERK activity. Treatment of 
the cells with piceid resulted into ERK1/2 (Figure 22A, 22C) and ERK5 (Figure 22B, 22C) 
phosphorylation, indicative of activation of these pathways. Significant increase in activation of 
ERK1/2 was observed at 5 min and ERK5 at 2 hr. It is important to note that for all the treatment 
points, the activation for ERK1/2 and ERK5 was higher than the control, except ERK5 activation 
is back to basal similar to control. 
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Figure 22. Piceid (RV8) causes activation (phosphorylation) of ERK1/2 and ERK5 in SH-
SY5Y cells 
Quantification of the immunoblots for ERK1/2 (A) and ERK5 (B) using Licor Odyssey software. 
The values are calculated using the integrated intensity. Protein expression was standardized to 
basal total protein. Data are expressed as mean ± standard error of the mean. *p<.0.05 compared 
to the 0 time point. (C) Representative immunoblots of total and phosphorylated ERK1/2 and 
total and phosphorylated ERK5 in SH-SY5Y cells indicating RV8 activates (phosphorylates) 
ERK1/2 and ERK5 in a time-dependent manner. U0126 (10µM) and XMD8-92 (10µM) were 
used as inhibitors of phosphorylated ERK1/2 and phosphorylated ERK5 respectively. 
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Inhibition of the ERK1/2 and ERK5 pathways attenuates piceid-mediated neuroprotection 
in SH-SY5Y cells 
To determine if activation of ERK1/2 and/or ERK5 was involved in piceid-mediated 
neuroprotection, we used pharmacological inhibitors of MEK1/2, kinases upstream of ERK1/2, 
and ERK5. SH-SY5Y cells were pretreated with 10μM of U0126, the MEK1/2 inhibitor, or 
XMD8-92, the ERK5 inhibitor, for 1 hr. Cells were then treated with piceid for 1hr following 
which they were exposed to 150μM of DA for 12 hr. The piceid-mediated protection against 
DA-induced cell loss was attenuated following inhibition of ERK1/2 and ERK5 activation 
(Figure 23A, 23B). These data suggest that ERK1/2 and ERK5 play a role in piceid-mediated 
neuroprotection of SH-SY5Y cells. 
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Figure 23.Inhibition of ERK1/2 and ERK5 activation independently in SH-SY5Y cells 
attenuates RV8-mediated neuroprotection 
SH-SY5Y cells were pretreated with U0126 (10µM) or XMD8-92 (10µM) followed by RV8 
(30µM) for 1 hr with or without DA. Cell Titer Glo (A) and Dead-protease fluorescence (B) 
were used to measure ATP levels and dead-cell protease levels respectively. Each experiment 
was performed 3 independent times and data is presented as mean ± standard error of mean. 
Statistical analysis was applied using one-way ANOVA followed by Dunnett's post hoc test. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. # indicates compared to vehicle while * and n.s. 
indicates compared to 150μM DA. 
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Piceid attenuates DA-induced oxidative stress in SH-SY5Y cells 
High concentrations of DA cause toxicity, partly via induction of oxidative stress. In our study, 
dopamine at 150μM caused a significant increase in the levels of malondialdehyde (MDA), a 
reactive carbonyl compound derived from lipid peroxides. Piceid (30μM) significantly attenuated 
this increase in MDA levels (Figure 24). These data indicate that reduction of DA-induced 
oxidative stress is one of the mechanisms responsible for piceid-mediated protection in SH-
SY5Y cells. 
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Figure 24. Piceid attenuated oxidative stress associated with DA- induced toxicity 
SH-SY5Y cells were exposed to DA (150μM) treatment in the presence or absence of RV8 
(30µM). Each experiment was performed 3 independent times and data is presented as mean ± 
standard error of mean. Statistical analysis was applied using one-way ANOVA followed by 
Dunnett's post hoc test. *p<0.05. # indicates compared to vehicle while * indicates compared to 
150μM DA. 
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Piceid attenuates DA-induced caspase-3/7 activity and increases levels of the anti-apoptotic 
protein Bcl-2 in SH-SY5Y cells 
The increase in oxidative stress has been known to modulate expression levels of Bcl-2 family 
members (anti-apoptotic and pro-apoptotic proteins), resulting in activation of caspase pathway, 
thereby, apoptotic cellular death. We tested the levels of expression of Bcl-2, an anti-apoptotic 
protein, following DA exposure. Treatment with DA caused a decrease in Bcl-2 expression, 
which was very effectively reversed by piceid pretreatment (Figure 25A, 25B). Caspases play 
key effector roles in apoptotic cell death. Activation of caspase-3/7 results in activation of DNA 
fragmentation factor, which further activates endonucleases to cleave DNA and results in 
apoptosis. To further investigate the mechanism of neuroprotection by piceid, we tested caspase-
3/7 activity in SH-SY5Y cells that were pretreated with piceid (10-30μM) and then exposed to 
DA (150μM). Piceid pretreatment inhibited the increase in caspase-3/7 levels in following DA 
treatment (Figure 25C).  These results indicate that piceid exerts its neuroprotective effects, in 
part, via inhibition of apoptotic cell death through up regulation of Bcl-2 protein and reduction in 
caspase-3/7 activity. A schematic of the proposed mechanism has been depicted in Figure 26.  
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Figure 25. Piceid (RV8) pretreatment attenuates DA-mediated apoptosis in SH-SY5Y cells 
(A) Representative immunoblot of total Bcl-2 in SH-SY5Y cells indicating RV8 inhibited DA-
induced loss of Bcl-2 expression (B) Quantification of Bcl-2 immunoblots using Licor Odyssey 
software. The values are calculated using the integrated intensity. Protein expression was 
standardized to α-tubulin. Data are expressed as mean ± standard error of the mean. *p<.0.05 
compared to the 0 time point. (C) SH-SY5Y cells were pretreated with indicated concentrations 
of RV8 (1 hr) with or without DA. Caspase 3/7 activity was used to measure apoptosis. Each 
experiment was performed 3 independent timesand data is presented as mean ± standard error of 
mean. Statistical analysis was applied using one-way ANOVA followed by Dunnett's post hoc 
test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. # indicates compared to vehicle while * 
indicates compared to 150μM DA. 
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Figure 26. Schematic of proposed neuroprotective mechanism of piceid 
The flowchart shows potential mechanistic intervention of piceid in the reduction of DA-induced 
oxidative stress and cellular death. Our study indicates piceid to reduce DA-induced oxidative 
stress mediated SH-SY5Y cellular death by 1) activation of ERK1/2 and ERK5 cellular signaling 
pathway and 2) reduction in caspase-3/7 activation thereby reducing apoptosis. 
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DISCUSSION 
In this study, we have examined the cytoprotective effect of piceid in the SH-SY5Y 
dopaminergic neuronal cell line against DA-induced toxicity. Another important mechanistic 
goal was to elucidate the underlying signaling mechanisms that could be possibly be involved in 
piceid-mediated neuroprotection. Our data show that DA induced dose-dependent cytotoxicity in 
SH-SY5Y cells, and DA-induced cell death was considerably attenuated by piceid (10-30μM) as 
measured by an increase in ATP levels and reduction in dead-cell protease levels following 
piceid treatment prior to DA exposure. This is in accordance with the piceid-mediated protection 
seen in cisplatin-induced oxidative stress in rats 267 and resveratrol-mediated protection against 
DA-induced cytotoxicity 238. 
Extracellular signal-regulated kinases (ERK), ERK1/2 and ERK5, are members of the MAPK 
family of proteins. ERK1/2 and/or ERK5 have been shown to promote the basal survival of DA 
neurons and inhibit neurotoxin induced oxidative stress in SH-SY5Y cells 263, 265. In order to 
determine whether activation of ERK1/2 and/or ERK5 is involved in piceid-mediated protection 
against DA-induced toxicity, SH-SY5Y cells were treated with piceid and ERK1/2 and ERK5 
activation were examined. Treatment with piceid resulted in activation of ERK1/2 and ERK5. 
This study, to our knowledge is the first study, which shows piceid-mediated activation of 
ERK5. However, our data slightly differ from other reports of ERK1/2 inhibition by piceid 
although most of those findings were observed in non-neuronal cell line models 268-269. These 
differences could be due to the use of different cell types 65, 180, 270-271.  In our study, we also 
observed that piceid activates ERK1/2 and ERK5 at different time points. Differential expression 
of ERK1/2 and ERK5 has been observed with different stimuli (Cavanaugh et al., 2001); 
including early development where activation of these kinases is regulated differently (Parmar et 
 88 
al., 2015). To examine the role of ERK activation in piceid-mediated protection, we inhibited the 
ERK1/2 and ERK5 pathways independently using U0126 and XMD8-92, respectively. Piceid-
mediated protection was attenuated following ERK1/2 and ERK5 inhibition, suggesting that both 
pathways may play a role in the neuroprotection afforded by piceid. Our findings are consistent 
with the earlier observations in SH-SY5Y cells that suggest the ERK1/2 and ERK5 activation 
protects against oxidative stress in SH-SY5Y cells 263, 272. 
Natural antioxidants have been shown to up regulate the expression of anti-apoptotic proteins 
(e.g. Bcl-2, Bcl-XL) or reduce the expression pro-apoptotic proteins (e.g. Bad), both of which 
result in decreases in cytochrome c release and caspase activity 273. Activation of caspase-3/7 
results in DNA fragmentation, cleavage and eventually apoptosis 274. Bcl-2, a member of the 
Bcl-2 family, plays a crucial role in maintaining mitochondrial membrane potential and has been 
shown to regulate caspase activation 275. In our study, DA treatment decreased Bcl-2 protein 
levels and increased caspase-3/7 activity in SH-SY5Y cells. These data suggest that the loss of 
viability noted following DA treatment of SH-SY5Y cells may be due to an increase in 
apoptosis. Piceid pretreatment inhibited the DA-mediated loss of Bcl-2 protein expression and 
activation of caspase-3/7 activity. These cytoprotective properties could be associated with the 
ability of piceid to minimize the loss of plasma membrane potential and mitochondrial 
membrane potential and maintained cellular homeostasis 276. Together these data suggest that 
piceid pretreatment decreases DA-mediated apoptosis.  
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CONCLUSION AND FUTURE DIRECTIONS 
In conclusion, we have shown that piceid can protect against DA-induced apoptotic cell death of 
human dopaminergic neuroblastoma SH-SY5Y cells through activation of the MAPKs ERK1/2 
or ERK5 and inhibition of caspase-3/7 activity. Further studies will test piceid in primary 
neuronal cultures and animal models of aging. A long-term animal study of piceid, testing 
bioavailability and other biopharmaceutical characters including pharmacokinetics and 
pharmacodynamics, will provide a better understanding of the metabolism of this compound in 
vivo and its potential in aging, obesity and neurodegenerative disorders. 
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